Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUT00206 pharmacoMRI Ketamine Challenge Study
NCT02935725Phase 1Completed
- Sponsor
- Autifony Therapeutics
- Start
- Oct 2016
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AUT00206 in schizophrenia (4 arms), sponsored by Autifony Therapeutics. Primary endpoint: Blood Oxygen Level Dependent pharmacoMRI signals at 15 weeks. Started Oct 2016; status: completed.
02
Drugs
AUT00206
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02935725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02935725.